Detalhe da pesquisa
1.
Quantitative evaluation of lesion response heterogeneity for superior prognostication of clinical outcome.
Eur J Nucl Med Mol Imaging
; 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38819668
2.
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
Lancet Oncol
; 24(7): 783-797, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414011
3.
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
Prostate
; 82(12): 1176-1185, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35538398
4.
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
Oncologist
; 24(9): 1149-e807, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31152080
5.
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
N Engl J Med
; 373(8): 737-46, 2015 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26244877
6.
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
Invest New Drugs
; 36(5): 919-926, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30083962
7.
Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center.
J Oncol Pharm Pract
; 24(5): 348-353, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28457192
8.
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.
Br J Cancer
; 116(7): 874-883, 2017 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28222071
9.
A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
Invest New Drugs
; 35(3): 290-297, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28004284
10.
ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer.
Mol Pharm
; 14(5): 1782-1789, 2017 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28388076
11.
Utilization and evaluation of noncore chemotherapy regimens within an academic medical center.
J Oncol Pharm Pract
; 23(7): 518-524, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27388159
12.
Intermittent versus continuous androgen deprivation in prostate cancer.
N Engl J Med
; 368(14): 1314-25, 2013 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-23550669
13.
A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer.
Invest New Drugs
; 34(2): 225-30, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26924129
14.
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.
Invest New Drugs
; 34(1): 112-8, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26581400
15.
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
Invest New Drugs
; 34(2): 168-75, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26666244
16.
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.
Invest New Drugs
; 33(1): 169-76, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25318436
17.
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
Invest New Drugs
; 33(2): 397-408, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25556680
18.
A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies.
Cancer Invest
; 33(10): 483-9, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26536061
19.
A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.
J Oncol Pharm Pract
; 21(6): 416-24, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24986793
20.
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer.
Invest New Drugs
; 32(2): 295-302, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23860642